Clinical Research and Medical
Information on the BT Test
What is the BT Test?
The Biomarker Translation Test, or the BT Test, is a blood test that detects and measures the levels of key biomarkers that are associated with breast cancer. A biomarker is a protein found in the blood whose presence can indicate the existence of disease.
The BT Test has successfully demonstrated an ROC accuracy of greater than 80 percent in studies involving breast cancer-positive and non-breast cancer subjects, the latter group being comprised of healthy subjects, as well as subjects with both estrogen-related and non-estrogen-related other cancers.
What clinical studies have been completed on the BT Test?
In clinical study
Provista Diagnostics , the clinical services subsidiary of Provista Life Sciences, enrolled a total of 430 women subjects: 275 from biopsy patients and 150 age-matched, statistically equivalent patients without cancer. With this clinical study Provista was able to an accuracy of detecting breast cancer of greater than 80 percent.
For more information on our study of the BT Test for breast cancer please download our
clinical study summary here.